CLDX Celldex Therapeutics, Inc.
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 744218 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-93.9%
TTM net income YoY-37.6%
TTM EPS YoY-26.9%
Revenue 3-yr CAGR-66.9%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-211,684.8%
Net margin-195,608.9%
FCF margin-164,391.8%
EBITDA margin-209,321.5%
Returns
ROE-49.5%
ROA-45.1%
ROIC (approx.)-44.6%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets10.0%
Debt / equity0.00x
Current ratio10.97x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-8.3%
Payout ratio—
Capex / revenue4,915.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q3*2026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q3*2025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $22,000 | $15,000 | $121,000 | $0 | $730,000 | $695,000 | $1.18M |
| R&D expense | $67.41M | $67.54M | $73.00M | $75.33M | $62.93M | $54.20M | $52.61M | $46.94M |
| SG&A expense | $14.84M | $13.10M | $11.45M | $11.94M | $10.69M | $10.39M | $10.82M | $10.26M |
| Operating income | -$82.25M | -$80.62M | -$84.44M | -$87.15M | -$73.62M | -$63.86M | -$62.74M | -$56.03M |
| Net income | -$75.56M | -$73.50M | -$78.69M | -$81.32M | -$67.04M | -$56.60M | -$53.80M | -$47.09M |
| EBITDA | -$81.09M | -$79.72M | -$83.58M | -$86.34M | -$72.79M | -$62.98M | -$61.87M | -$55.21M |
| EPS (basic) | -0.96 | -0.94 | -1.18 | — | -1.01 | -0.85 | -0.81 | — |
| EPS (diluted) | -0.96 | -0.94 | -1.18 | — | -1.01 | -0.85 | -0.81 | — |
| Weighted avg. shares (diluted) | 78.53M | 77.84M | 66.57M | — | 66.42M | 66.39M | 66.38M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $26.95M | $47.45M | $35.73M | $28.87M | $36.04M | $23.04M | $17.14M | $28.36M |
| Short-term investments | $623.37M | $670.13M | $415.73M | $489.70M | $547.19M | $607.29M | $656.15M | $696.92M |
| Current assets | $663.74M | $724.93M | $459.22M | $534.66M | $604.34M | $648.40M | $693.76M | $747.16M |
| PP&E, net | $11.00M | $9.76M | $7.40M | $5.33M | $4.83M | $4.39M | $4.60M | $4.35M |
| Intangibles | $27.19M | $27.19M | $27.19M | $27.19M | $27.19M | $27.19M | $27.19M | $27.19M |
| Total assets | $721.53M | $782.35M | $511.25M | $582.98M | $648.44M | $692.41M | $739.47M | $792.34M |
| Current liabilities | $60.52M | $61.33M | $51.47M | $50.99M | $46.47M | $32.96M | $32.02M | $39.50M |
| Total liabilities | $72.06M | $67.78M | $55.03M | $55.82M | $50.08M | $37.00M | $36.49M | $45.34M |
| Shareholders' equity | $649.47M | $714.56M | $456.23M | $527.16M | $598.36M | $655.41M | $702.98M | $747.00M |
| Shares outstanding | 78.53M | 78.50M | 66.57M | 66.55M | 66.45M | 66.39M | 66.38M | 66.37M |
| Cash flow statement | ||||||||
| Operating cash flow | -$65.03M | -$57.41M | -$65.59M | -$63.94M | -$48.63M | -$44.01M | -$54.37M | -$32.48M |
| Capital expenditure | $1.67M | $3.18M | $1.64M | $1.28M | $440,000 | $728,000 | $265,000 | $756,000 |
| Free cash flow | -$66.70M | -$60.59M | -$67.23M | -$65.22M | -$49.07M | -$44.73M | -$54.64M | -$33.23M |
| Investing cash flow | $43.42M | -$255.52M | $72.12M | $55.42M | $60.85M | $49.85M | $42.95M | $24.05M |
| Financing cash flow | $1.11M | $324.66M | $327,000 | $1.35M | $774,000 | $63,000 | $202,000 | $386,000 |
| Depreciation & amortization | $1.16M | $902,000 | $854,000 | $816,000 | $824,000 | $873,000 | $867,000 | $819,000 |
| Stock-based compensation | $10.97M | $8.41M | $8.52M | $8.91M | $8.80M | $9.19M | $9.32M | $9.78M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.